Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + Fulvestrant in HR+ Metastatic Breast Cancer
NCT00534417Phase 2Completed
- Sponsor
- Accelerated Community Oncology Research Network
- Start
- Oct 2007
- Primary completion
- Sep 2011
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and fulvestrant in breast cancer, sponsored by Accelerated Community Oncology Research Network. Primary endpoints: Time to Progression at 29 months and Progression-free Survival at 32.5 months. Started Oct 2007; status: completed.
02
Drugs
capecitabinefulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00534417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00534417.